Literature DB >> 9713590

p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.

G Busatto1, Y H Shiao, A R Parenti, R Baffa, A Ruol, M Plebani, M Rugge.   

Abstract

BACKGROUND: Upregulation of the cell cycle associated genes, p16/CDKN2 and the retinoblastoma susceptibility gene (Rb), is commonly seen during the proliferation of normal cells. An inverse relation between the expression of p16/CDKN2 and Rb has been noted in many tumours, but has not yet been determined in oesophageal squamous carcinoma. AIMS: To investigate p16/CDKN2 genetic alterations and both the p16/CDKN2 and the Rb protein (pRb) immunophenotypes in oesophageal squamous carcinoma.
METHODS: Twenty primary oesophageal squamous carcinomas were examined for mutations in p16/CDKN2 by the polymerase chain reaction, single stranded conformational polymorphism, and DNA sequencing. Synthesis of p16/CDKN2 and pRb proteins was determined by immunohistochemistry in 19 specimens of formalin fixed, paraffin wax embedded tissues.
RESULTS: Mutations of p16/CDKN2 were not detected in exons 1 and 2. In only one case, G to C and C to T base changes were detected in a non-coding region of exon 3. Expression of p16/CDKN2 and Rb was observed in both normal and neoplastic areas of tissue sections, indicating neither consistent homozygous deletion nor consistent hypermethylation of the genes in tumours. Fourteen tumours showed an inverse expression of p16/CDKN2 and Rb. An increased percentage of cells that immunostained positively for p16/CDKN2 but not for pRb was observed in eight tumours, five of which had no detectable pRb, suggesting defective Rb expression in these oesophageal squamous carcinomas.
CONCLUSIONS: These results indicate that p16/CDKN2 mutations occur infrequently in oesophageal squamous carcinoma. The alteration of the Rb gene is suggested as an important step in the development of these tumours.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713590      PMCID: PMC395614          DOI: 10.1136/mp.51.2.80

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  32 in total

1.  p16 gene in uncultured tumours.

Authors:  C H Spruck; M Gonzalez-Zulueta; A Shibata; A R Simoneau; M F Lin; F Gonzales; Y C Tsai; P A Jones
Journal:  Nature       Date:  1994-07-21       Impact factor: 49.962

2.  Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.

Authors:  X Zhou; H Suzuki; Y Shimada; M Imamura; J Yin; H Y Jiang; L Tarmin; J M Abraham; S J Meltzer
Journal:  Genes Chromosomes Cancer       Date:  1995-08       Impact factor: 5.006

3.  Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing.

Authors:  M Gonzalez-Zulueta; C M Bender; A S Yang; T Nguyen; R W Beart; J M Van Tornout; P A Jones
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

4.  Mutations and altered expression of p16INK4 in human cancer.

Authors:  A Okamoto; D J Demetrick; E A Spillare; K Hagiwara; S P Hussain; W P Bennett; K Forrester; B Gerwin; M Serrano; D H Beach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract.

Authors:  H Igaki; H Sasaki; Y Tachimori; H Kato; H Watanabe; T Kimura; Y Harada; T Sugimura; M Terada
Journal:  Cancer Res       Date:  1995-08-01       Impact factor: 12.701

6.  MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines.

Authors:  Q Liu; Y X Yan; M McClure; H Nakagawa; F Fujimura; A K Rustgi
Journal:  Oncogene       Date:  1995-02-02       Impact factor: 9.867

7.  Growth suppression by p16ink4 requires functional retinoblastoma protein.

Authors:  R H Medema; R E Herrera; F Lam; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

8.  Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.

Authors:  S W Tam; J W Shay; M Pagano
Journal:  Cancer Res       Date:  1994-11-15       Impact factor: 12.701

9.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16.

Authors:  J Lukas; D Parry; L Aagaard; D J Mann; J Bartkova; M Strauss; G Peters; J Bartek
Journal:  Nature       Date:  1995-06-08       Impact factor: 49.962

10.  Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.

Authors:  D Parry; S Bates; D J Mann; G Peters
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

View more
  4 in total

1.  Mutations in epidermal growth factor receptor gene in esophageal squamous cell carcinoma patients in kashmir- a high incidence area of India.

Authors:  Mohammad Muzaffar Mir; Nazir A Dar; Irfana Salam; Zaffar A Shah
Journal:  Int J Health Sci (Qassim)       Date:  2008-07

2.  pRB expression in esophageal mucosa of individuals at high risk for squamous cell carcinoma of the esophagus.

Authors:  Simone S Contu; Paulo C Contu; Daniel C Damin; Renato B Fagundes; Fabiano Bevilacqua; Aline S Rosa; João C Prolla; Luis F Moreira
Journal:  World J Gastroenterol       Date:  2007-03-21       Impact factor: 5.742

3.  Analysis of the Cycilin D1/p16/pRb Pathway in Parathyroid Adenomas.

Authors:  Eva Cristobal; Begona Arribas; Juan Tardio; Jose A. AIcazar; Juan C. Matinez-Montero; Rafael Carrion; Jose R. Polo; Laura Gil; Marta Azanedo; Jose M. Rojas; Javier Menarguez
Journal:  Endocr Pathol       Date:  2000       Impact factor: 3.943

4.  Epidermal growth factor receptor (EGFR) mutations and expression in squamous cell carcinoma of the esophagus in central Asia.

Authors:  Behnoush Abedi-Ardekani; Nazir Ahmad Dar; Mohammad Muzaffar Mir; Showkat Ahmad Zargar; M Muqbool Lone; Ghyslaine Martel-Planche; Stéphanie Villar; Mounia Mounawar; Farrokh Saidi; Reza Malekzadeh; Pierre Hainaut
Journal:  BMC Cancer       Date:  2012-12-17       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.